Non-viral Lung Gene Editing for Cystic Fibrosis Therapy:
Two CFF funded Research Associate/Fellow positions (for 3 years and 1 year)
- Location: Biodiscovery Institute, University of Nottingham
- Salary: £27,511 to £33,797 per annum, depending on skills and experience (minimum £30942 with relevant PhD)
- Closing date: 15th July 2020
We are currently seeking two Research Associate/Fellows to join a multidisciplinary research project funded by the Cystic Fibrosis Foundation (CFF) – ‘Mucus-penetrating Peptide Nanoparticles for gene augmentation of CFTR’ – to undertake research on the design and development of a novel class gene therapy for the genetic correction CF by gene augmentation and gene editing strategies. The successful candidates will join highly motivated and well-funded research teams within the Schools of Pharmacy and Medicine, co-located in state-of-the-art facilities in the multidisciplinary University of Nottingham Biodiscovery Institute (BDI) on the main University Park campus. This project is in collaboration with Johns Hopkins University (JHU) USA, and the University of Edinburgh (Roslin Institute).
The Research Associate/Fellows will design, develop and execute formulation of gene delivery peptide nanoparticles. These activities involve: 1) nanoparticle formulation/characterisation, 2) in vitro assessments using human airway cell cultures and Ussing analyses, 3) Aiding the JHU team in vivo testing, 4) Aiding the Edinburgh team in in vivo testing. 5) vector design formulation/characterization, 6) in vitro assessment of editing using human airway cell cultures, 7) Synergising with the second fellow working on the nanoparticle formulation and vector engineering and gene editing aspects of the project. S/he will be either a cell-culture expert and be heavily involved in the ALI culture set up and Ussing analyses; or an expert in gene delivery and editing technologies.
Candidates should have or be close to completion of a PhD in molecular and/or cell biology, together with a keen interest in respiratory medicine and gene therapy/ editing.
There are 2 full time posts available; 1) a fixed term contract until 31 January 2023 and 2) a fixed term contract for one year (with possible extension, subject to funding).
Informal enquiries may be addressed to:
Dr James Dixon
Please note that applications sent directly to this email address will not be accepted.